Autoinjectors Market - Global Drivers' Restraints' Opportunities' Trends' and Forecast: 2018-2024
Overview: The medical devices that are primarily used for the self-injection of drugs' classically life-saving drugs' are known as autoinjectors. These devices are gaining increased importance for the management of anaphylaxis' diabetes' rheumatoid arthritis' multiple sclerosis' and others. Autoinjectors are relaxed to use and proposed for self-administration by individuals either at caretakers premises or at home.
Raising prevalence of serious medical conditions such as anaphylaxis & other food allergies' advancements in the autoinjectors technology' increasing demand for home healthcare' and the rising need for self-injectors are the factors aiding the growth of the autoinjectors market. Novel formulations of drugs and advancements in drug delivery systems along with favorable government regulations are providing an opportunity for the market growth. However' recent product recalls by the companies and the availability of substitutes for autoinjectors are hampering the market growth.
Market Analysis: The "global autoinjectors market" is estimated to witness a CAGR of 17.1% during the forecast period 2018-2024. The autoinjectors market is analyzed based on three segments - products' applications' and regions.
Regional Analysis: The regions covered in the report are North America' Europe' Asia Pacific' and Rest of the World (ROW). North America accounts for the largest share of the autoinjectors market' followed by Europe' Asia Pacific' and Rest of the World. More than 65% of the market is occupied by North America' with the US being the major contributor to the market growth.
Product Analysis: Based on the products' the market is segmented into disposable autoinjectors and reusable autoinjectors. Disposable autoinjectors hold dominant market share and is also the fastest growing segment in the market.
Application Analysis: Based on the application areas' the market is segmented into anaphylaxis' multiple sclerosis' rheumatoid arthritis' diabetes' and others. The market is dominated by anaphylaxis owing to a high prevalence rate globally. The fastest growing segment of the market is rheumatoid arthritis due to increased development of novel drugs for the treatment of the condition.
Key Players: The major players in the market are Mylan NV' Novartis AG' Amgen' Inc.' Becton Dickinson and Company' Bayer AG' and Eli Lilly & Company Ltd. The other key players in the market include Ypsomed Holding AG' Biogen Pharmaceuticals' Pfizer Inc.' Teva Pharmaceutical' Antares Pharma' Inc.' Johnson and Johnson' and AbbVie' Inc.
Competitive Analysis: The key manufacturers of autoinjectors are concentrating on innovative marketing tactics to expand the reach of their products globally. Increasing awareness campaigns and price reduction of branded devices are among the strategies used by the leading companies to manage intense competition in the market. Many companies are rebranding their autoinjectors with worthwhile reductions in the price. In December 2016' Mylan launched the generic version of EpiPen to provide autoinjector for customers at lesser prices. This approach ought to help the company in targeting a larger customer pool' thus increasing the company's customer base in recent years.
Benefits: The report provides complete details about the usage and adoption rate of autoinjectors in various regions. With that' key stakeholders can know about the major trends' drivers' investments' and vertical player's initiatives. Moreover' the report provides details about the major challenges that are going to impact on the market growth. Additionally' the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:




Region/Country Cover in the Report

(North America' Europe' Asia Pacific' and Rest of the World).

Key Players Covered in the Report

Mylan NV
Novartis AG
Amgen' Inc.
Becton Dickinson and Company
Bayer AG
Eli Lilly & Company Ltd Ypsomed Holding AG' Biogen Pharmaceuticals' Pfizer Inc.' Teva Pharmaceutical' Antares Pharma' Inc.' Johnson and Johnson' and AbbVie Inc